Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]

Author(s): Fulvio Gualtieri, Luca Guandalini, Dina Manetti, Elisabetta Martini, Maria N. Romanelli

Journal Name: Medicinal Chemistry Reviews - Online (Discontinued)

Volume 2 , Issue 6 , 2005


Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and agerelated pathologies such as MCI and AD. Development of cognition enhancers is still a difficult task because of the complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. Current research is based on several working hypotheses, derived from the progress of knowledge in the neuro-bio-pathology of cognitive processes. Approaches followed to develop cognition enhancing drugs, the results obtained in the past few years (since 2000) and the most promising molecules under study are reviewed.

Keywords: NMDA receptor antagonist, AMPA receptor, NSAIDs, acetylcholinesterase (AChE) inhibitors, Neuromodulation, Aniracetam

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [471 - 487]
Pages: 17
DOI: 10.2174/156720305775009643
Price: $58

Article Metrics

PDF: 1